Page last updated: 2024-09-03

y 27632 and Dysmyelopoietic Syndromes

y 27632 has been researched along with Dysmyelopoietic Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Basiorka, AA; Caceres, G; Clark, J; Heaton, R; Johnson, JO; List, AF; McGraw, KL; Ozawa, Y; Padron, E; Sokol, L; Wei, S	1

Other Studies

1 other study(ies) available for y 27632 and Dysmyelopoietic Syndromes

Article	Year
Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PloS one, 2014, Volume: 9, Issue:12 Topics: Actins; Aged; Aged, 80 and over; Amides; Cell Line, Tumor; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Female; Humans; Immunologic Factors; Lenalidomide; Male; Membrane Microdomains; Myelodysplastic Syndromes; Protein Multimerization; Pyridines; Receptors, Erythropoietin; rho-Associated Kinases; Signal Transduction; Thalidomide	2014

Article

Year

Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.

PloS one, 2014, Volume: 9, Issue:12

Topics: Actins; Aged; Aged, 80 and over; Amides; Cell Line, Tumor; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Female; Humans; Immunologic Factors; Lenalidomide; Male; Membrane Microdomains; Myelodysplastic Syndromes; Protein Multimerization; Pyridines; Receptors, Erythropoietin; rho-Associated Kinases; Signal Transduction; Thalidomide

2014